180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has closed on its previously announced public offering. The offering was comprised of 4,615,385 shares of the company’s common stock (or common stock equivalents in lieu thereof) as well as warrants to purchase up to 4,615,385 shares of common stock at a purchase price per share (and accompanying warrant) of $0.65. According to the announcement, the warrants were immediately exercisable, also at $0.65 per share; the warrants will expire on Oct. 10, 2028. The company announced that gross proceeds from the offering totaled an estimated $3 million, before deducting fees and other offering expenses. 180 Life Sciences anticipates using the funds from the public offering for R&D as well as legal expenses and general corporate purposes, including the preparation of a marketing authorization application for Dupuytren’s Contracture in the United Kingdom and possibly the United States. A.G.P./Alliance Global Partners acted as the sole placement agent for the offering.
To view the full press release, visit https://ibn.fm/P1st6
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research and, where appropriate, combination therapy. The company’s current primary focus is a novel program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). For more information about the company, visit www.180LifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
